What You Should Know:
– Lys Therapeutics, a French biotechnology company, has announced a $5M grant award from The Michael J. Fox Foundation for Parkinson’s Research (MJFF).
– The significant funding, part of MJFF’s Therapeutic Pipeline Program, will accelerate the clinical development of LYS241, a first-in-class monoclonal antibody for the treatment of Parkinson’s disease and other neurodegenerative disorders. The grant will support the completion of preclinical development and the launch of first-in-human clinical trials.
Breakthrough Mechanism Targeting the Blood-Brain Barrier
LYS241 is a novel therapeutic approach designed to target the pathological mechanisms associated with blood-brain barrier (BBB) dysfunction, which is a central process in many neurological diseases. BBB impairment allows toxic molecules and inflammatory cells to enter the central nervous system, leading to neuroinflammation and neuronal death.
Unlike conventional therapies that must cross the BBB, LYS241 works from within the blood vessels. Specifically, it is designed to block the interaction between tissue plasminogen activator (tPA) and the NMDA receptor (NMDAr) in the vascular compartment. By doing so, it restores BBB integrity and interrupts the cascade of events, including dopaminergic neuron degeneration, that leads to neurodegeneration. This approach targets a fundamental cause of disease progression instead of limiting treatment to symptom control.
“Pipeline-in-a-Drug” Potential
The MJFF award is a strong validation of the science behind LYS241. It supports Lys Therapeutics’ “pipeline-in-a-drug” strategy—developing LYS241 for multiple neurological diseases driven by BBB dysfunction and neuroinflammation. Beyond Parkinson’s disease, LYS241 has demonstrated potent disease-modifying effects in validated preclinical models of multiple system atrophy, ischemic stroke, and multiple sclerosis.
“We are honored by the continued trust of The Michael J. Fox Foundation. This grant is both a strong validation of the science behind LYS241 and a powerful catalyst for our development program. It enables us to move with confidence toward clinical evaluation, with the goal of offering patients a truly novel therapeutic option.” said Dr. Manuel Blanc, CEO and co-founder of Lys Therapeutics.
